GET DAILY SIGNALSRelmada Therapeutics (RLMD) Analyst Targets Point to +185% Upside
Key Takeaways
- The central target of $12 is the arithmetic mean of six verified analyst price targets, rounded from roughly $12.30; individual targets span approximately $8 to $19.
- At a recent price around $4.20, reaching $12 implies upside of roughly 185% — a very large move by any standard.
- Coverage is predominantly Buy-rated, but one firm (Weiss Ratings) has published a Sell view, and the wide target range signals unusually high uncertainty.
- RLMD is a pre-revenue, clinical-stage biotech whose value depends on a repositioned pipeline: NDV-01 for non-muscle invasive bladder cancer and sepranolone for neuropsychiatric conditions.
- Key supports include a roughly $217.7 million cash balance funding operations into 2029 and upcoming IND (investigational new drug) filings.
- Principal risks are binary clinical and regulatory outcomes, no marketed product or revenue, potential dilution, and resistance well below the target.
- For additional context, explore Relmada's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Readers can also explore Trending AI Robots for automated, AI-driven market screening and trading ideas.
Breaking Down the Analyst Consensus
Relmada Therapeutics, Inc. (RLMD) draws attention from a limited set of analysts, with targets that differ substantially. I reviewed six verified figures: Mizuho at $19 (raised from $10 in March 2026), Lucid Capital at $14 (initiated March 2026), H.C. Wainwright at $12 (initiated June 2026), Piper Sandler at $12 (initiated March 2026, Overweight), Jefferies at $9 (December 2025), and Leerink Partners at roughly $8 (January 2026). The arithmetic mean lands near $12.30, which rounds to a central target of $12. The spread from about $8 to $19 stands out as unusually broad, highlighting real differences in how analysts value this pre-commercial pipeline. Some aggregators show averages between roughly $10.75 and $14.33 depending on their coverage window, so no single number qualifies as an official consensus. Ratings lean heavily toward Buy, though Weiss Ratings has issued a Sell opinion, indicating the shares are not viewed as undervalued across the board. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Price Levels and the Path to the Target
RLMD has traded recently near $4.20, inside a 52-week range of roughly $2.97 to $8.00. Hitting the $12 central target would mean a gain of about 185% from that point — a substantial move, particularly since the shares have not reached or exceeded $12 in recent history and the prior 52-week high sits at only $8. The company remains pre-revenue and operates as a binary, event-driven biotech. Its lead program, NDV-01, is a sustained-release intravesical formulation of gemcitabine and docetaxel aimed at non-muscle invasive bladder cancer, with an IND filing expected by year-end 2026 and a planned Phase 3 “RESCUE” registrational study. A second candidate, sepranolone, is a neurosteroid advancing toward a Phase 2 proof-of-concept study for neuropsychiatric conditions. Any lasting re-rating would most likely follow positive clinical data, regulatory progress, or a strategic transaction rather than steady operational gains.
Factors That Could Support Progress Toward the Target
The bull case centers on the repositioned pipeline and a solid balance sheet. Relmada reported roughly $217.7 million in cash as of June 30, 2026, which management projects will fund operations into 2029. That runway lowers near-term dilution risk and provides time to advance both programs. Analyst targets well above the current price reflect the belief that the oncology opportunity, especially NDV-01 for bladder cancer, is not yet priced into a market capitalization of roughly $416–455 million. Near-term catalysts include the two IND filings and the start of registrational and proof-of-concept studies. The stock’s low beta of about 0.57 and mostly Buy-rated coverage add some support, though they offer no assurance of gains.
Risks That Could Keep the Target Out of Reach
The core risk remains that neither candidate reaches the market. As a pre-revenue company with roughly 17 employees and no approved products, Relmada’s valuation rests almost entirely on future clinical and regulatory success. A failed trial, delayed IND, or manufacturing issue could push the stock toward or below its 52-week low. The wide target range itself serves as a caution: analysts cannot agree on whether the company is worth $8 or $19. Additional concerns include possible future equity raises despite the extended cash runway, competition in bladder cancer and CNS disorders, and the earlier failure of the company’s prior lead depression program in Phase 3, which illustrates how quickly clinical-stage value can disappear.
Technical Levels and Market Structure
The shares currently sit roughly midway between the 52-week low near $2.97 and the high of $8.00. The $8 level represents the strongest overhead resistance and would need a decisive break before a move into double digits looks realistic. On the downside, the $3 area forms a key support zone, with the psychological $5 level in between. Because the $12 target lies 50% above the prior high, the technical picture alone does not back the target; reaching it would require a fundamental catalyst strong enough to break the longer-term range.
Time Horizon and Key Items to Watch
Most analyst price targets reflect a research horizon of roughly 12 months, though individual firms do not always state this explicitly. For a pre-revenue biotech, that horizon effectively means “through the next major data or regulatory milestone” rather than a fixed calendar date. Investors should monitor the year-end 2026 IND filings for NDV-01 and sepranolone, clearance and launch of the Phase 3 RESCUE program, quarterly cash updates and any financing moves, plus analyst revisions after news events. Any of these developments could shift the target range meaningfully in either direction.
Using AI Daily Buy/Sell Signals for Context
For traders who prefer a systematic approach to a volatile name like RLMD, Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to fundamental research. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to identify new opportunities, track existing positions, and detect shifting trends more efficiently than manual checks alone. Exploring the signals helps place analyst targets in a real-time, price-action context. I find this approach useful when evaluating event-driven names, as it adds an objective layer to the broader research process without replacing core analysis.
Final Assessment
The $12 central target represents the arithmetic mean of six analyst price targets spanning roughly $8 to $19, and it sits about 185% above the recent price near $4.20. Reaching it would require a very large move driven by successful execution of a repositioned, pre-revenue pipeline. The strongest supports are a lengthy cash runway and upcoming regulatory catalysts, while the principal obstacles are binary clinical risk, no revenue, and a target range so wide it underscores genuine uncertainty. Given the spread between the highest and lowest targets and the absence of an approved product, investors should treat $12 as an illustrative scenario tied to future milestones — not a forecast — and monitor the IND filings, the start of the registrational program, and analyst revisions as the next meaningful signposts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RLMD in upward trend: price rose above 50-day moving average on November 06, 2026
RLMD moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RLMD as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RLMD just turned positive on October 20, 2026. Looking at past instances where RLMD's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for RLMD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for RLMD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RLMD broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.014) is normal, around the industry mean (3.498). P/E Ratio (-4.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases
Industry Biotechnology